· It recorded a turnover of 4.6 million euro, 26.4% up on 2003
Granada / Madrid, 24 February 2004. PULEVA BIOTECH chalked up a net profit of 1.9 million euro in 2003, 57.3% up on the profits posted in 2002. Its net turnover totalled 4.6 million euro, representing a year-on-year growth of 26.4%.
PULEVA BIOTECH pushed ahead during 2003 with the provision of R+D+i services for other companies while taking great strides in its own research and development activities.
Several new technologies were also implemented in PULEVA BIOTECH in 2003, including molecular evolution techniques for the production of proteins and other metabolites of nutritional interest, a genomic research platform to study the effects of different nutrients and foods on the expression of certain genes, and a metabolic unit to assess the effects of functional foods on humans.
During 2003 the company began implementing a standardised R+D+i management system, in accordance with AENOR standard 166.002, official certification of which is expected to be obtained in 2004.
Negotiation of collaboration agreements with multinationals
Finally, the company embarked in 2003 on an ambitious commercial plan for the provision of R+D+i services and marketing of own products. Collaboration agreements are being negotiated with leading multinational enterprises, which PULEVA BIOTECH hopes to close this year.
